甘李藥業(603087.SH):GZR18美國I期臨牀試驗完成首例受試者入組
格隆匯3月10日丨甘李藥業(603087.SH)公佈,公司自主研發的GZR18正在開展美國I期臨牀試驗,於近日成功完成首例受試者入組。
GZR18為每週注射一次的胰高血糖素樣肽-1(“GLP-1”)受體激動劑類藥物,此次臨牀試驗擬開發適應症為2型糖尿病。
胰高血糖素樣肽-1(GLP-1)可以調節多種調控血糖激素的分泌,以葡萄糖依賴性的方式促進胰島素分泌和抑制胰高血糖素釋放,而這些在2型糖尿病患者中是受損的。與胰島素注射劑相比,由於GLP-1促進胰島素分泌呈葡萄糖濃度依賴性,因此相較於胰島素注射劑,GLP-1受體激動劑類(GLP-1RA)降糖藥可以降低低血糖發生率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.